Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9-CAR.B7-H3 T cells in Triple Negative Breast Cancer
NCT06347068Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jun 2024
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-CAR.B7-H3 T cells in triple-negative breast cancer (TNBC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Toxicity: NCI-CTCAE at 4 weeks, Cytokine Release Syndrome at 8 weeks and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
iC9-CAR.B7-H3 T cells
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06347068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06347068.